Treatment | < 1970 | 1970–79 | 1980–89 | 1990–99 | 2000–2013 |
---|---|---|---|---|---|
No therapy | 399 (75.6%) | 38 (6.8%) | 27 (4.2%) | 30 (4.4%) | 33 (3.9%) |
Surgery only | 41 (7.8%) | 102 (18.2%) | 85 (13.1%) | 116 (17.1%) | 162 (19.0%) |
Chemotherapy only | 30 (5.7%) | 135 (24.1%) | 174 (26.7%) | 270 (39.8%) | 405 (47.5%) |
Radiotherapy only | 49 (9.3%) | 145 (25.9%) | 88 (13.5%) | 46 (6.8%) | 17 (2.0%) |
Radiotherapy and chemotherapy | 9 (1.7%) | 140 (25.0%) | 277 (42.6%) | 217 (32.0%) | 236 (27.7%) |
Total | 528 (100%) | 560 (100%) | 651 (100%) | 679 (100%) | 853 (100%) |
Number (%) | Any subsequent malignant neoplasm | Non-melanoma skin cancer | Benign meningioma | ||
---|---|---|---|---|---|
All survivors | 3271 (100%) | 183 (100%) | 56 (100%) | 34 (100%) | |
Gender | Male | 1830 (55.9%) | 77 (42.1%) | 30 (54%) | 14 (41%) |
Female | 1441 (44.1%) | 106 (57.9%) | 26 (46%) | 20 (59%) | |
Leukaemia | 870 (26.6%) | 23 (12.6%) | 11 (20%) | 14 (41%) | |
Hodgkin’s lymphoma | 315 (9.6%) | 51 (27.9%) | 17 (30%) | 2 (6%) | |
Non-Hodgkin’s lymphoma | 277 (8.5%) | 16 (8.7%) | 4 (7%) | 2 (6%) | |
Central nervous system tumour | 625 (19.1%) | 25 (13.7%) | 12 (21%) | 15 (44%) | |
Neuroblastoma | 124 (3.8%) | 6 (3.3%) | 1 (2%) | 0 (0%) | |
Retinoblastoma | 60 (1.8%) | 0 (0%) | 0 (0%) | 0 (0%) | |
Wilms’ tumour | 143 (4.4%) | 9 (4.9%) | 1 (2%) | 1 (3%) | |
Childhood cancer | Bone tumour | 199 (6.1%) | 13 (7.1%) | 0 (0%) | 0 (0%) |
type | Soft-tissue sarcoma | 224 (6.8%) | 14 (7.7%) | 4 (7%) | 0 (0%) |
Germ cell | 168 (5.1%) | 8 (4.4%) | 3 (5%) | 0 (0%) | |
Liver | 27 (0.8%) | 1 (0.5%) | 1 (2%) | 0 (0%) | |
Thyroid | 86 (2.6%) | 8 (4.4%) | 1 (2%) | 0 (0%) | |
Nasopharyngeal carcinoma | 13 (0.4%) | 4 (2.2%) | 1 (2%) | 0 (0%) | |
Melanoma | 75 (2.3%) | 2 (1.1%) | 0 (0%) | 0 (0%) | |
Carcinoma | 59 (1.8%) | 3 (1.6%) | 0 (0%) | 0 (0%) | |
Other | 6 (0.2%) | 0 (%) | 0 (0%) | 0 (0%) | |
Mean | 9.4 (6.0) | 11.2 (5.7) | 11.3(6.0) | 7.0 (4.1) | |
Age at childhood | 0–4 | 1065 (32.6%) | 39 (21.3%) | 13 (23%) | 12 (35%) |
cancer diagnosis (years) | 5–9 | 656 (20.1%) | 34 (18.6%) | 9 (16%) | 15 (44%) |
10–14 | 690 (21.1%) | 49 (26.8%) | 13 (23%) | 5 (15%) | |
15–19 | 860 (26.3%) | 61 (33.3%) | 21 (38%) | 2 (6%) | |
< 1970 | 528 (16.1%) | 22 (12.0%) | 4 (7%) | 3 (9%) | |
Decade of | 1970–79 | 560 (17.1%) | 50 (27.3%) | 18 (32%) | 11 (32%) |
diagnosis of childhood cancer | 1980–89 | 651 (19.9%) | 63 (34.4%) | 22 (39%) | 16 (47%) |
1990–2000 | 679 (20.8%) | 32 (17.5%) | 9 (16%) | 3 (9%) | |
2000–2018 | 853 (26.1%) | 16 (8.7%) | 3 (5%) | 1 (3%) | |
0–19 | 1643 (50.2%) | 31 (16.9%) | 4 (7%) | 2 (6%) | |
20–29 | 550 (16.8%) | 33 (18.0%) | 4 (7%) | 7 (21%) | |
Attained age | 30–39 | 494 (15.1%) | 59 (32.2%) | 20 (36%) | 19 (56%) |
(years) | 40–49 | 353 (10.8%) | 33 (18.0%) | 19 (34%) | 5 (15%) |
50–59 | 151 (4.6%) | 19 (10.4%) | 7 (12%) | 0 (0%) | |
60+ | 80 (2.4%) | 8 (4.4%) | 2 (4%) | 1 (3%) | |
No therapy | 527 (16.1%) | 4 (2.2%) | 9 (16%) | 2 (6%) | |
Surgery only | 506 (15.5%) | 24 (13.1%) | 3 (5%) | 0 (0%) | |
Treatment childhood of cancer | Chemotherapy | 1014 (31.0%) | 40 (21.9%) | 17 (30%) | 2 (6%) |
Radiotherapy | 345 (10.5%) | 44 (24.0%) | 27 (48%) | 11 (32%) | |
Radiotherapy and chemotherapy | 879 (26.9%) | 71 (38.8%) | 9 (16%) | 19 (56%) |
Childhood type / SN cancer | ALL AML | HL | NHL | CNS | Neuroblastoma | Retinoblastoma | Wilms | Bone sarcoma | Soft tissue sarcoma | Germ cell | Liver | Thyroid | Nasopharyngeal carcinoma | Melanoma | Carcinoma | Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Meningioma | 14 | 2 | 2 | 15 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34 |
NMSC | 11 | 17 | 4 | 12 | 1 | 0 | 1 | 0 | 4 | 3 | 1 | 1 | 1 | 0 | 0 | 56 |
Breast (C50 D05) | 1 | 14 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 0 | 1 | 1 | 1 | 2 | 26 |
CNS (C70-C72) | 6 | 0 | 0 | 11 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 |
Digestive (C15-C26) | 1 | 3 | 4 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 13 |
Genitourinary (C51-C68, D09, D06) | 3 | 3 | 2 | 4 | 0 | 0 | 2 | 5 | 7 | 3 | 1 | 5 | 0 | 1 | 0 | 36 |
Leukaemia (C90-C93) | 3 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
Lymphoma (C81-C85) | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
Melanoma (C43, D03) | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 4 |
Bone (C40-C41) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
Head&Neck (C00-C14) | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 9 |
Other | 1 | 3 | 1 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 9 |
Respiratory (C30-C39) | 0 | 4 | 3 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 12 |
Soft-tissue (C49) | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 5 |
Thyroid (C73) | 2 | 19 | 3 | 6 | 1 | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 37 |
Total | 48 | 70 | 22 | 52 | 7 | 0 | 11 | 13 | 18 | 11 | 2 | 9 | 5 | 2 | 3 | 273 |
SMN (ICD10) | All ages | 0-39 years | 40+ years | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Obs | Exp | SIR (95%CI) | AER (95%CI) | Obs | Exp | SIR (95%CI) | AER (95%CI) | Obs | Exp | SIR (95%CI) | AER (95%CI) | |
All sites | 183 | 63.2 | 2.9 (2.5,3.3) | 257 (213,307) | 123 | 34.9 | 3.5 (2.9,4.2) | 216 (173,266) | 60 | 28.2 | 2.1 (1.6,2.7) | 545 (372,770) |
Head & Neck (C00-C14) | 9 | 1.4 | 6.4 (2.9,12.1) | 16 (7,33) | 5 | 0.3 | (5.8,41.517.8 ) | 12 (4,28) | 4 | 1.1 | 3.5 (1.0,9.0) | 49 (10,147) |
Digestive organs (C15-C26) | 13 | 5.5 | 2.4 (1.3,4.1) | 16 (7,32) | 7 | 1.0 | 6.8 (2.8,14.1) | 15 (5,32) | 6 | 4.4 | 1.4 (0.5,2.9) | 27 (2,112) |
Respiratory organs (C30-C39) | 12 | 2.9 | 4.2 (2.2,7.4) | 20 (9,37) | 5 | 0.2 | (7.6,54.523.3 ) | 12 (4,28) | 7 | 2.6 | 2.7 (1.1,5.5) | 75 (22,185) |
Bone (C40-C41) | 2 | 0.4 | 5.1 (0.6,18.3) | 3 (0,14) | 2 | 0.3 | 5.8 (0.7,21.0) | 4 (0,16) | 0 | 0.0 | 0.0 (.,73.9) | 0 |
Melanoma of skin (C43, D03) | 4 | 4.2 | 1.0 (0.3,2.4) | 0 | 3 | 2.2 | 1.4 (0.3,4.0) | 2 (0,13) | 1 | 2.0 | 0.5 (0.0,2.8) | 0 |
Soft tissue (C49) | 5 | 0.5 | 9.5 (3.1,22.2) | 10 (3,23) | 4 | 0.4 | (3.1,28.711.2 ) | 9 (2,24) | 1 | 0.2 | 5.9 (0.1,32.9) | 14 (0,90) |
Breast (C50, D05) | 26 | 6.6 | 3.9 (2.6,5.7) | 41 (25,65) | 16 | 1.6 | (5.9,16.710.3 ) | 35 (20,59) | 10 | 5.1 | 2.0 (0.9,3.6) | 84 (27,198) |
Genitourinary (C51-C68, D09, D06) | 36 | 32.2 | 1.1 (0.8,1.5) | 8 (2,21) | 22 | 23.3 | 0.9 (0.6,1.4) | 0 | 14 | 8.9 | 1.6 (0.9,2.6) | 87 (28,201) |
Central nervous system (C70-C72) | 18 | 1.3 | (7.9,21.213.4 ) | 36 (21,57) | 13 | 0.9 | (7.6,24.414.3 ) | 30 (15,52) | 5 | 0.4 | (3.8,27.011.6 ) | 78 (24,190) |
Thyroid gland (C73) | 37 | 1.7 | (15.2,29.721.6 ) | 76 (53,105) | 30 | 1.1 | (18.5,39.027.3 ) | 71 (47,102) | 7 | 0.6 | (4.6,23.411.3 ) | 109 (42,233) |
Lymphoma (C81-C85) | 3 | 2.8 | 1.1 (0.2,3.2) | 0 (0,9) | 3 | 2.0 | 1.5 (0.3,4.4) | 3 (0,14) | 0 | 0.8 | 0.0 (.,4.6) | 0 |
Leukemia (C90-C93) | 9 | 1.5 | 6.0 (2.8,11.4) | 16 (7,32) | 8 | 1.0 | 8.0 (3.5,15.8) | 17 (7,35) | 1 | 0.5 | 2.0 (0.1,11.2) | 9 (0,80) |
Factor | Level | any SMN |
AER (95%CI) | RER (95%CI) | ||
---|---|---|---|---|---|---|
O | SIR (95%CI) | RR (95%CI) | ||||
Overall | All combined | 183 | 2.9 (2.5,3.3) | – | 2.6 (2.1,3.2) | -- |
Male | 77 | 4.0 (3.2,5.0) | 1.0 (ref.) | 2.3 (1.7,3.1) | 1.0 (ref.) | |
Sex | Female | 106 | 2.4 (2.0,2.9) | 0.7 (0.5-1.0) | 2.9 (2.1,4.0) | 1.4 (0.9-2.1) |
Pheterogeneity* | <0.001 | 0.03 | 0.30 | 0.16 | ||
Age at | 0–4 | 39 | 3.9 (2.8,5.3) | 1.0 (ref.) | 2.0 (1.3,3.1) | 1.0 (ref.) |
diagnosis | 5–9 | 34 | 3.3 (2.3,4.6) | 0.9 (0.6-1.6) | 2.4 (1.5,4.0) | 0.8 (0.4-1.6) |
of childhood | 10–14 | 49 | 3.1 (2.3,4.1) | 0.9 (0.5-1.5) | 3.2 (2.1,4.9) | 0.7 (0.4-1.5) |
cancer | 15–19 | 61 | 2.3 (1.8,2.9) | 0.8 (0.5-1.3) | 2.7 (1.7,4.3) | 0.6 (0.3-1.2) |
(years) | Ptrend* | 0.01 | 0.3 | 0.23 | 0.13 | |
< 1970 | 22 | 1.4 (1.0,2.2) | 1.0 (ref.) | 1.2 (0.3,4.8) | 1.0 (ref.) | |
Decade of | 1970–1979 | 50 | 3.4 (2.6,4.5) | 1.7 (1.0-3.0) | 4.1 (2.8,6.1) | 3.4 (1.0-11.9) |
diagnosis of | 1980–1989 | 63 | 4.0 (3.1,5.1) | 1.7 (0.9-3.0) | 3.8 (2.7,5.3) | 3.5 (1.0-12.5) |
childhood | 1990–2000 | 32 | 2.7 (1.9,3.8) | 1.1 (0.5-2.1) | 1.8 (1.0,3.1) | 2.6 (0.7-9.7) |
cancer | 2000–2018 | 16 | 2.7 (1.7,4.4) | 0.9 (0.4-2.0) | 1.2 (0.5,2.5) | 2.5 (0.6-10.4) |
Ptrend* | 0.07 | 0.3 | 0.02 | 0.61 | ||
Era | < 1995 | 151 | 2.9 (2.5,3.4) | 1.0 (ref.) | 3.1 (2.4,3.9) | 1.0 (ref.) |
diagnosis | > = 1995 Pheterogeneity* | 32 | 2.8 (2.0,4.0) 0.88 | 0.7 (0.5-1.1) 0.15 | 1.4 (0.8,2.5) 0.01 | 1.0 (0.6-1.8) 0.9 |
< 20 | 31 | 10.6 (7.4,15.0) | 1.0 (ref.) | 1.5 (1.0,2.2) | 1.0 (ref.) | |
20–29 | 33 | 2.2 (1.6,3.1) | 0.2 (0.1-0.4) | 1.4 (0.7,2.5) | 1.0 (0.5-2.0) | |
30–39 | 59 | 3.5 (2.7,4.5) | 0.3 (0.2-0.5) | 5.1 (3.6,7.3) | 3.4 (1.9-6.1) | |
Attained | 40–49 | 33 | 2.7 (1.9,3.8) | 0.2 (0.1-0.4) | 5.2 (3.0,9.0) | 3.4 (1.5-7.4) |
Age (yrs) | 50–59 | 19 | 2.0 (1.3,3.1) | 0.2 (0.1-0.4) | 6.6 (2.7,16.3) | 7.5 (2.8-20.4) |
60+ | 8 | 1.3 (0.6,2.6) | 0.1 (0.1-0.4) | 3.7 (0.2,90.4) | 10.8 (1.6-74.0) | |
Ptrend* | <0.001 | <0.001 | <0.001 | <0.001 | ||
0–9 | 38 | 6.0 (4.3,8.2) | 1.0 (ref.) | 1.6 (1.1,2.3) | 1.0 (ref.) | |
Time diagnosis since | 10–19 | 37 | 2.6 (1.9,3.6) | 0.4 (0.3-0.7) | 1.7 (1.0,2.9) | 1.1 (0.6-2.0) |
of | 20–29 | 51 | 3.1 (2.4,4.1) | 0.4 (0.2-0.6) | 4.3 (2.9,6.5) | 2.5 (1.4-4.4) |
childhood | 20–39 | 36 | 2.6 (1.9,3.6) | 0.3 (0.2-0.6) | 5.7 (3.4,9.6) | 3.4 (1.7-6.9) |
cancer (years) | 40+ | 21 | 1.7 (1.1,2.5) | 0.2 (0.1-0.4) | 5.3 (1.8,15.5) | 5.2 (2.1-12.4) |
Ptrend* | <0.001 | <0.001 | <0.001 | <0.001 | ||
Leukaemia | 23 | 2.7 (1.8,4.0) | 1.0 (ref.) | 1.6 (0.8,3.0) | 1.0 (ref.) | |
Hodgkin’s lymphoma | 51 | 5.0 (3.8,6.6) | 2.5 (1.4-4.2) | 6.5 (4.6,9.1) | 2.8 (1.4-5.7) | |
non-Hodgkin’s lymphoma | 16 | 4.3 (2.7,7.1) | 1.7 (0.9-3.3) | 3.3 (1.7,6.2) | 1.3 (0.5-3.6) | |
Central nervous system tumour | 25 | 2.8 (1.9,4.2) | 1.2 (0.7-2.2) | 2.1 (1.1,3.8) | 1.1 (0.5-2.4) | |
Neuroblastoma | 6 | 5.1 (2.3,11.3) | 1.8 (0.7-4.5) | 3.2 (1.2,8.6) | 1.8 (0.6-5.5) | |
Retinoblastoma | 0 | 0 | - | 0 | - | |
Wilms Tumour | 9 | 3.8 (2.0,7.3) | 1.4 (0.6-3.1) | 2.6 (1.1,6.3) | 1.0 (0.3-3.3) | |
Type of | Bone sarcoma | 13 | 2.7 (1.6,4.6) | 1.6 (0.8-3.3) | 3.3 (1.4,7.8) | 1.8 (0.6-5.0) |
childhood cancer | Soft-tissue sarcoma | 14 | 2.6 (1.5,4.4) | 1.2 (0.6-2.3) | 2.3 (1.0,5.4) | 1.1 (0.4-2.9) |
Germ-cell | 8 | 1.6 (0.8,3.1) | 0.9 (0.4-2.1) | 1.0 (0.1,6.7) | 0.6 (0.1-3.0) | |
Liver | 1 | 7.9 (1.1,56.1) | 2.2 (0.3-16.3) | 3.2 (0.3,30.4) | 2.1 (0.2-19.2) | |
Thyroid | 8 | 2.0 (1.0,4.0) | 1.2 (0.5-2.7) | 2.3 (0.6,8.9) | 0.9 (0.2-4.0) | |
Nasopharyngeal carcinoma | 4 | 7.5 (2.8,20.0) | 4.2 (1.4-12.8) | 12.6 (4.1,39.1) | 6.9 (1.9-24.6) | |
Melanoma | 2 | 0.4 (0.1,1.8) | 0.3 (0.1-1.4) | 0.1 | 0 | |
Carcinoma | 3 | 1.1 (0.4,3.4) | 0.8 (0.2-2.6) | 0.2 | 0 | |
Pheterogeneity* | <0.001 | <0.001 | <0.001 | <0.001 | ||
No therapy treatment of childhood | 4 | 0.4 (0.2,1.1) | 0.3 (0.1-0.8) | 0 | - | |
Surgery only | 24 | 1.7 (1.1,2.5) | 1.0 (ref.) | 1.0 (0.4,2.7) | 1.0 (ref.) | |
Treatment of | Chemotherapy | 40 | 3.3 (2.4,4.4) | 1.8 (1.1-3.1) | 2.2 (1.4,3.4) | 4.6 (1.0-20.9) |
childhood cancer | Radiotherapy | 44 | 4.4 (3.3,5.9) | 2.6 (1.6-4.3) | 5.7 (3.9,8.4) | 7.3 (1.6-33.5) |
Radio and chemotherapy | 71 | 4.3 (3.4,5.4) | 2.4 (1.5-3.9) | 3.8 (2.8,5.2) | 7.0 (1.6-30.8) | |
Pheterogeneity* | <0.001 | <0.001 | <0.001 | <0.001 |
Decade of diagnosis | All survivors |
|
---|---|---|
Dead | Alive | |
< 1970 | 447 | 81 |
1970–1979 | 394 | 166 |
1980–1989 | 309 | 342 |
1990–2000 | 222 | 457 |
2000–2013 | 155 | 698 |
Total | 1527 | 1744 |